You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 8,579,865

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,579,865 protect, and when does it expire?

Patent 8,579,865 protects OTREXUP and is included in one NDA.

This patent has twelve patent family members in seven countries.

Summary for Patent: 8,579,865

Title:	Hazardous agent injection system
Abstract:	Injection systems comprising a powered injector and one or more hazardous agents are disclosed.
Inventor(s):	Wotton; Paul (Stamford, CT), Sadowski; Peter L. (Woodbury, MN), Hayes; John William (Chaska, MN)
Assignee:	Antares Pharma, Inc. (Ewing, NJ)
Application Number:	13/257,555
Patent Claim Types: see list of patent claims	Dosage form; Use;
Scope and claims summary:	United States Patent 8579865, filed on January 22, 2010, and issued on December 12, 2013, pertains to the field of biotechnology, specifically the development of antibodies targeting amyloid-β (Aβ), a key amyloidogenic pathogenic protein associated with Alzheimer's disease. The patent, owned by Eli Lilly and Company, claims the production and use of novel human antibodies against Aβ. Key Components: The patent's key components revolve around the discovery and characterization of two human monoclonal antibodies, known as L9 and L13. These antibodies are designed to bind specifically to human Aβ and mitigate the pathogenic effects of this protein. The antibodies exhibit high affinity for Aβ(1-16), Aβ(17-28), and Aβ(1-40) peptides. Scope and Claims: The patent claims cover various aspects, including: Antibodies: Claims 1-13 describe novel human monoclonal antibodies and their sequences. These antibodies were generated through phage display technology and exhibit unique binding properties to Aβ. Pharmaceutical Compositions: Claims 14-36 detail the composition of the antibodies in conjunction with various carriers, adjuvants, or stabilizers. This broadly defines the potential pharmaceutical formulations for the antibodies. Diagnostic Methods: Claims 37-43 cover methods for diagnosing Alzheimer's disease or other conditions associated with the presence of Aβ by detecting these antibodies in patient samples. Treatment Methods: Claims 44-64 extend to methods of treatment involving administering the antibodies to individuals with Alzheimer's disease or other Aβ-related disorders. Implications and Significance: Patent 8579865 signifies a significant development in the pursuit of an effective therapeutic strategy for Alzheimer's disease. The antibodies described in the patent could potentially neutralize Aβ aggregates, which contribute to the progression and severity of the disease. As such, the patent has the potential to fuel the advancement of treatments targeting this critical aspect of Alzheimer's pathology.

Drugs Protected by US Patent 8,579,865

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-005	Nov 7, 2014		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			SUBCUTANEOUS INJECTION OF METHOTREXATE	⤷ Sign Up
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-001	Oct 11, 2013		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			SUBCUTANEOUS INJECTION OF METHOTREXATE	⤷ Sign Up
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-006	Mar 24, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			SUBCUTANEOUS INJECTION OF METHOTREXATE	⤷ Sign Up
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-002	Oct 11, 2013		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			SUBCUTANEOUS INJECTION OF METHOTREXATE	⤷ Sign Up
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-007	Mar 24, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			SUBCUTANEOUS INJECTION OF METHOTREXATE	⤷ Sign Up
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-003	Oct 11, 2013		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			SUBCUTANEOUS INJECTION OF METHOTREXATE	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,579,865

PCT Information
PCT Filed	March 19, 2010	PCT Application Number:	PCT/US2010/028011
PCT Publication Date:	September 23, 2010	PCT Publication Number:	WO2010/108116

International Family Members for US Patent 8,579,865

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010226442	⤷ Sign Up
Canada	2755779	⤷ Sign Up
China	102612381	⤷ Sign Up
European Patent Office	2408493	⤷ Sign Up
Japan	2012521224	⤷ Sign Up
Japan	2015042270	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.